Previous 10 | Next 10 |
New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, was recently the focus of coverage by leading fina...
Longeveron, Inc. (LGVN) Q4 2020 Earnings Conference Call March 30, 2021 8:30 AM ET Company Participants Natalya Rudman – Senior Vice President-Crescendo Communications Geoff Green – Chief Executive Officer Joshua Hare – Co-Founder, Chief Science Officer and Chairman James...
Longeveron shares up ([[LGVN]] +11.0%) after the company posted fourth-quarter results and provided a business update listing out its achievements during the period. Total revenue for the quarter fell 33% to $1.2M year-over-year, as the company dealt with a fall in grant revenue during t...
Longeveron (LGVN): Q4 Net loss of $1.4MRevenue of $1.2M (-33.3% Y/Y)Press Release For further details see: Longeveron reports Q4 results
MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today reported its financial results for the quarter and full...
MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at 8:30 a....
MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Gree...
MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the underwriters of its previousl...
Gainers: NLS Pharmaceutics NLSP +111%, Entera Bio ENTX +75%, Seelos Therapeutics SEEL +34%, Regulus Therapeutics (RGLS) +27%, Rafael (RFL) +27%.Losers: Marker Therapeutics MRKR -28%, Timber Pharmaceuticals (TMBR) -21%, Evoke Pharma EVOK...
Marker Therapeutics MRKR -24% after prices stock offering.Timber Pharmaceuticals (TMBR) -25%.Evoke Pharma EVOK -24% on Q4 earnings release.FinVolution (FINV) -15%.Poshmark POSH -15% on Q4 earnings release; after Q1 revenue guidance falls short.AMMO POWW ...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market ...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today ann...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...